ArticleOncogene2019

Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.

Joan Cao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.